This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of Sjögren's syndrome along with the positive topline results from the Phase 2 DAHLIAS study

Ticker(s): JNJ

Who's the expert?

Institution: Cleveland Clinic

  • Rheumatologist with a special interest in epidemiology of rheumatic diseases.
  • Currently manages 300 patients with RA and 100 with SLE
  • Research Focus: epidemiology of sarcoidosis and has published over 30 original articles describing this under-studied disease.

Interview Goal
The focus of this interview will be on the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of Sjögren's syndrome along with the positive topline results from the Phase 2 DAHLIAS study.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.